ReviewJournal for immunotherapy of cancer2018
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Michael M Boyiadzis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
121 papers cite itlatest 60 shown
this paperpooled ittrialcites it